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Enteroviruses
CNSEnteroviruses (EV) frequently infect the central nervous system (CNS) and induce neurological diseases.
Although the CNS is composed of many different cell types, the spectrum of tropism for each EV is
considerable. These viruses have the ability to completely shut down host translational machinery and are
considered highly cytolytic, thereby causing cytopathic effects. Hence, CNS dysfunction following EV infection
of neuronal or glial cells might be expected. Perhaps unexpectedly given their cytolytic nature, EVs may
establish a persistent infection within the CNS, and the lasting effects on the host might be signiﬁcant with
unanticipated consequences. This review will describe the clinical aspects of EV-mediated disease,
mechanisms of disease, determinants of tropism, immune activation within the CNS, and potential treatment
regimes.
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Enterovirus (EV) infections are a signiﬁcant cause of morbidity and
mortality throughout the world. The EV genus is part of the
picornavirus family and includes such notable members as poliovirus
(PV), coxsackievirus (CV), and enterovirus-71 (EV-71). EVs have been
associated with many human diseases, including myocarditis (Klingel
et al., 1992), pancreatitis (Ramsingh, 2008), and chronic inﬂammatory
myopathy (Tam and Messner, 1999). Diseases caused by EV are not
restricted to the well-known scourge of mankind throughout history,
recognized as poliomyelitis. Many non-polio human EVs are quite
common, causing an estimated 10–15 million or more symptomatic
infections in the US alone. Non-polio EVs are known to target the
central nervous system (CNS) and are responsible for numerous
clinical manifestations, including encephalitis, and meningitis
(Michos et al., 2007). The long-term consequences of EV infection
upon the CNS are largely unknown. However, these viruses are known
to persist, and the presence of viral RNA by itself has been shown to be
potentially pathogenic in some cases. Also, EVs have been linked to
autoimmune-like diseases, including diabetes, chronic inﬂammatory
myopathy, and chronic myocarditis, perhaps in part due to the long-
term presence of viral material. Therefore, EVs may be able to persist
within the CNS potentially causing lasting neuropathology.
The original classiﬁcation of enteroviruses included the four
groups: Polioviruses (PVs), Coxsackie A viruses, Coxsackie B viruses,
and ECHO (Enteric Cytopathic Human Orphan) viruses. However, the
signiﬁcant level of phylogenetic overlap among the four groups has
led to a new classiﬁcation system of consecutive numbers for the
more recently isolated viruses (such as Enterovirus-71, Enterovirus-
72, etc.) (Oberste et al., 2002). Our review will cover the most
common and more extensively studied types of enteroviruses.
However, the large number of circulating strains in human popula-
tions alone suggests a potential role for these viruses for unknown or
unappreciated human diseases (Victoria et al., 2009). Also, vaccine
design against enteroviruses may be difﬁcult based on signiﬁcant EV
genetic variability.Polioviruses (PVs)
Polioviruses (PVs) are perhaps the most studied and character-
ized of the enteroviruses, especially given the clinical consequences
of infection which can infect motor neurons of the anterior horn of
the spinal cord and lead to paralytic poliomyelitis in humans.
Although the advent of polio vaccination has proven effective in
greatly reducing the incidence of disease, some cases still occur and
these cases appear to be on the rise; outbreaks following wild PV
importations into previously polio-free countries continue to be an
ongoing risk (MMWR, 2010). Over the years, basic research on PV has
revealed the mechanics of protein translation and viral replication,
immune activation, vaccine development, and viral population
dynamics (Cameron et al., 2010; Pfeiffer, 2010). These discoveries
have provided valuable information for the ongoing research of non-
polio enteroviruses which continue to cause encephalitis and meningitis
in humans.Coxsackieviruses (CVs)
Coxsackieviruses (CVs) may cause severe morbidity and mortality,
particularly in the very young (Romero, 2008; Tebruegge and Curtis,
2009). CV infection during pregnancy has been linked to an increase
in spontaneous abortions, fetal myocarditis (Ornoy and Tenenbaum,
2006), and neurodevelopmental delays in the newborn (Euscher et al.,
2001). Infants infected with CV have been shown to be extremely
susceptible to myocarditis, meningitis and encephalitis with a
subsequent mortality rate as high as 10%. Also, a number of delayed
neuropathologies have been associated with previous CV infection,
including schizophrenia (Rantakallio et al., 1997; Suvisaari et al.,
2003), encephalitis lethargica (Cree et al., 2003), and amyotrophic
lateral sclerosis (Woodall and Graham, 2004; Woodall et al., 1994). Of
note, few studies have been done to determine the lasting
consequences of CV infection upon surviving individuals despite the
relatively common occurrence of CV meningo-encephalitis in infants.
Enterovirus-71 (EV-71)
Enterovirus-71 (EV-71) is amajor public health issue acrossAsia and
of increasing concern globally, causing hand foot and mouth disease
with potential neurological complications (Solomon et al., 2010). The
brain stem is themost likely target for infection, and infectionmay cause
serious clinical disease and psychological disorders in young children
(Lee et al., 2009). New outbreaks of EV-71 have occurred across Asia,
perhaps due to the ability of the virus to rapidly evolve (Solomon et al.,
2010).
Echoviruses (ECHO-Vs) and parechoviruses (P-ECHO-Vs)
Echoviruses (ECHO-Vs) were ﬁrst isolated from the feces of
asymptomatic patients; however, these viruses are now recognized
to be associated with various human diseases, including aseptic
meningitis. ECHO-Vs are highly infectious and preferentially target
infants and young children. These viruses can cause amild, nonspeciﬁc
illness similar to that of CVs. Also, parechoviruses (P-ECHO-Vs) have
been found to be associated with encephalitis and white matter injury
in neonates (Gupta et al., 2010; Verboon-Maciolek et al., 2008a), with
similarities to EV infections (Verboon-Maciolek et al., 2008b).
Although originally described as ECHO-V-22 and ECHO-V-23, their
distinct genetic features have led to their re-classiﬁcation (Harvala and
Simmonds, 2009).
Theiler's murine encephalomyelitis virus (TMEV)
Although the picornavirus, Theiler's murine encephalomyelitis
virus (TMEV), is designated a cardiovirus by phylogenetic analyses,
much can be learned from the existing literature on TMEV and CNS
disease. Also, many similarities exist between EVs and TMEV in terms
of their molecular biology, tropism, ability to persist, and induction of
neuropathology. Therefore, we have included relevant information on
TMEV and CNS pathology in this review. Two main subtypes of TMEV
are studied in animal models. The strain GDVII produces acute
encephalomyelitis quickly in mice. The DA, WW, or BeAn strains
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those seen in multiple sclerosis. More detailed reviews of TMEV
tropism, immune response, persistence, and demyelination have been
published by other research groups (Brahic et al., 2005; Lipton et al.,
2005; Oleszak et al., 2004; Olson et al., 2005; Rodriguez, 2007).
Molecular biology of enteroviruses
To better understand EV infection of the CNS and potential
consequences upon glial or neuronal host cells, a full comprehension
of EV structure and molecular biology is essential. EVs consist of
icosahedral, non-enveloped viruses of approximately 30 nm in
diameter. These viruses generally have the proclivity to survive acidic
environment, enabling their passage through the stomach following
fecal/oral transmission and eventual invasion into the small intestine.
The viral capsid contains the positive-strand RNA genome, ranging in
size from ~7.2 to 8.5 kb. The viral genome includes several cis-acting
RNA elements which play a role in replication and/or translation.
These cis-acting elements include the 5′ and 3′ nontranslated regions
(NTRs), the cis-acting replication element (CRE) and the 3′ poly(A)
tail (Steil and Barton, 2009).
A single open reading frame (ORF) within the NTRs encodes a long
viral protein which undergoes post-translational cleavage into the
mature viral proteins. These viral proteins include the four structural
proteins, VP1–4 which comprise the viral capsid, and seven non-
structural proteins (2A–C and 3A–D) including the primer- and RNA-
dependent RNA polymerase (3DPol) (Kitamura et al., 1981). In
addition, one of the viral proteins 3B (also known as VPg) covalently
attaches to the 5′ end of the viral genome. VPg plays an essential role
in viral replication by acting as a primer for RNA synthesis. Utilizing
PV as a model, VPg has been shown to undergo uridylylation to
VPgpUpU by 3DPol using adenosine residues in the stem-loop
structure of CRE, located in the 2C region of the EV ORF, as a template
(Goodfellow et al., 2000; Paul et al., 2003). Recent elucidation by NMR
suggests that VPg undergoes a structural change upon uridylylation
which allows viral replication to be more efﬁcient and selective
(Schein et al., 2010). Since uridylylation is not observed during host
cell transcription, this process may be a unique therapeutic target
against EV infections, given that point mutations that block
uridylylation may prevent viral growth (Paul et al., 1998). While
VPg plays a role in both positive- and negative-strand RNA synthesis,
it is still unknown how approximately 40 to 70 copies of positive-
strand genome are produced for every negative-strand genome
during an EV infection (Novak and Kirkegaard, 1991). Intriguingly,
this ratio decreases upon the establishment of CVB3 persistence
within the CNS suggesting that a double-stranded RNA genomic
structuremight assist in virus stability during persistence (Feuer et al.,
2009).
Despite the unanswered questions with regards to the ratio of EV
positive to negative strand synthesis during both acute and persistent
infection, many other aspects of their translation and replication are
well understood. For example, the well-characterized internal ribo-
some entry site (IRES) in the 5′ NTR directly interacts with host cell
ribosomes to initiate translation of the viral genome upon entering
the cell (Pelletier and Sonenberg, 1988). Immediate translation is
necessary in order to produce the primer- and RNA-dependent RNA
polymerase needed for viral replication, as well as the other viral
proteins that facilitate replication. The viral genome is translated into
a ~250-kDa polyprotein, which undergoes a series of cleavages at
predetermined cleavage sites carried out by the viral proteases 2Apro
and 3CDpro. During proteolytic processing, several precursor protein
intermediates also play important roles during viral infection.
Only after viral protein translation is completed does negative-
strand replication begin since translation and replication cannot occur
at the same time (Gamarnik and Andino, 1998). A ternary complex
then forms to facilitate both positive- and negative-strand synthesis atthe 5′ cloverleaf structure of the 5′NTR that includes the host poly(rC)
binding protein (PCBP) and the viral precursor protein 3CD (Vogt and
Andino, 2010). This complex associates with poly(A) binding protein
1 (PABP1), which is bound to the poly(A) tail of the genome, and
causes the genome to circularize during negative-strand synthesis
(Herold and Andino, 2001). Further analysis of the crystal structure of
3CD has shown that the N-terminus is in close proximity to the VPg
binding site, and that 3CD may be involved in the uridylylation
reaction as part of the replication complex (Marcotte et al., 2007).
Moreover, 3AB (also the VPg precursor protein) is a membrane bound
protein (Fujita et al., 2007), thus providing a spatial link between viral
replication on host membranes, viral priming and the replication
complex.
Enteroviruses and autophagy
Interestingly, EVs have been shown to beneﬁt from, and induce the
cellular degradation process known as autophagy (Huang et al., 2009;
Suhy et al., 2000; Wong et al., 2008). It is thought that EVs use the
autophagosome membrane as a scaffold for viral replication. A recent
publication has shown an increase in viral replication linked to the
induction of autophagy during CV infection in rat primary neurons
(Yoon et al., 2008). Autophagy is known to play an important role in
preventing cellular damage in neurons, and this normal cellular
process has recently been shown to be highly upregulated in neurons
during short-term fasting (Alirezaei et al., 2010; Simonsen et al.,
2008).
However, it still remains to be determined if EVs use autophagy for
viral replication in all cell types within the CNS. For example, given
their unique and critical role in development and CNS cellular
homeostasis, neural stem cells might respond differently and
uniquely to microbial infection. Furthermore, it will be important to
elucidate whether autophagy plays a role in the establishment of viral
persistence in the CNS. The induction or inhibition of autophagy in
cells harboring viral material may alter EV persistence. Autophagy
inhibitors have been shown to preferentially decrease extracellular as
compared to intracellular PV production, thus providing an attractive
model for non-cytolytic virus release from the cell (Jackson et al.,
2005). Also, one might expect that an increase in the level of
autophagy which might recycle organelles or other cellular compo-
nents associated with EV persistence may hasten viral RNA
degradation.
Host cell translational shutdown following enterovirus infection
In addition to their roles in viral replication and post-translational
processing, several viral proteins have profound effects on the host
cell during the course of infection effectively modulating cellular
transcription, translation and protein secretion. Host cell transcription
is suppressed by the viral protease 3C, which is carried into the
nucleus by the nuclear localization signal located on 3D when in its
precursor form (Sharma et al., 2004). Additionally, the 3C protein of
EV-71 has recently been shown to block polyadenylation of host
mRNA by cleaving a critical factor needed for this process (Weng et al.,
2009). In turn, viral protease 2A halts host cell cap-dependent
translation by cleaving eIF4G, which in a clever twist also enhances
the translation of viral mRNA by stabilizing polysomes (Etchison et al.,
1982; Kempf and Barton, 2008). Furthermore, viral proteins 2B and 3A
inhibit host cell protein secretion, as plasma membrane and secretory
protein transport are halted (Doedens and Kirkegaard, 1995).
In general, the host cell most likely faces a grim ultimate fate due
the cytolytic nature of EVs. Viral protein 2B is a highly efﬁcient
viroporin which can permeabilize the host cell membrane, as well as
those of nearby cells (Madan et al., 2010). However, the pathways
activated in the cell during infection can be somewhat contradictory.
In what is thought to be an attempt by the virus to keep the cell alive
Fig. 1. Neural progenitor and stem cells grown in culture are highly susceptible to
coxsackievirus infection. NPSCs were isolated from the cortices of one day-old C57 BL/6
mice, cultured to form neurosphere aggregates, and infected with eGFP-CVB3
(moi=0.1). Infected neurospheres were observed over time by ﬂuorescence
microscopy. Virus protein expression (green) was readily observed by day 1 PI. An
increase in viral protein expression was seen until day 4 PI. By day 6 PI, virus protein
levels were reduced, and signs of cytopathic effect (cpe) were readily observed at a
higher magniﬁcation (not shown).
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cellular conﬁnements, EVs induce both anti-apoptotic (3A and 2B
proteins) and pro-apoptotic effects (VP2, 2A and 3C proteins) on the
host cell (Whitton et al., 2005). Furthermore, viral protein synthesis,
which is boosted by 2A, has been shown to be necessary for apoptosis
(Shih et al., 2008). With several reports demonstrating apoptosis in
neurons after EV infection, and the role of 2A in regulating translation,
it is interesting to speculate that shutoff of host cell translation by EVs
may directly cause apoptotic cell death in neurons. We have shown
that CVB3 induced apoptosis within pyramidal neurons in the
hippocampus (Feuer et al., 2003). In contrast, TMEV may indirectly
induce apoptosis of nearby pyramidal neurons in the hippocampus in
non-cell autonomous manner (Buenz et al., 2009).
Virus entry — cell receptors
EVs use a wide array of receptors and entry mechanisms to invade
the host cell. In particular, EV-71 has been shown to use several
receptors, including sialylated glycans, P-selectin glycoprotein ligand-1
and Scavenger receptor B2 (Nishimura et al., 2009; Yamayoshi et al.,
2009; Yang et al., 2009). CVB can utilize both decay accelerating factor
(DAF) and the coxsackievirus and adenovirus receptor (CAR) for viral
entry, depending on the target cell. For example in polarized cells, CVB
elicits a unique strategy by binding to DAF at the apical surface of the
cell, followed by CAR binding within the tight junctions in a caveolin-
dependent, dynamin-independent manner (Coyne and Bergelson,
2006). Whereas in non-polarized cells, CVB only appears to utilize
CAR for entry and undergoes dynamin-dependent and caveolin-
independent entry (Patel et al., 2009).
While some EVs are capable of utilizingmultiple receptors, PV uses
only one, CD155, an adhesion molecule also known as the human PV
receptor (hPVR). In an in vitro blood-brain barrier (BBB)model, PV has
been show to enter human brain microvascular endothelial cells
(hBMECs) using hPVR in a dynamin and caveolin-dependent manner
(Coyne et al., 2007). However, when using non-CNS speciﬁc
immortalized cells lines, PV entry was found to be caveolin-
independent. Both reports found tyrosine kinases to be essential for
entry (Brandenburg et al., 2007). These studies illustrate the
importance of characterizing EV entry in multiple CNS cell types,
since key differences may exist in different model systems of
infection. Similarly, care must be taken in making generalized
conclusions of virus entry based on in vitro cell culture models.
Undoubtedly, receptor expression on potential target cells deﬁnes
the ﬁrst barrier to virus entry. A recent study has shown a link
between decreased CAR expression in differentiated primary neurons
and a reduction in CVB3 infection, suggesting that susceptibility to
infection may diminish as the level of virus receptor decreases during
the differentiation process (Ahn et al., 2008). Similarly, PV infection
and tissue tropism was largely found to be restricted by hPVR
expression in the CNS of hPVR promoter-driven beta-galactosidase
transgenic mice (Gromeier et al., 1995). Analysis of receptor
distribution in hPVR promoter-driven beta-galactosidase transgenic
mice during development showed high levels of protein expression in
the spinal cord anterior horn motor neurons which are known to
harbor infection in the mature CNS (Gromeier et al., 2000). Although
some EV receptors may be widely expressed in tissues including the
CNS, additional cellular determinants may ultimately control tropism.
For example, CAR expression is relatively widespread in the murine
neonatal CNS (Honda et al., 2000; Hotta et al., 2003; Venkatraman
et al., 2005) and utilized by adenovirus— a DNA virus with substantial
tropism differences as compared to CVB3. Yet, early CVB3 infection is
largely restricted to neural progenitor and stem cells (NPSCs) (Fig. 1)
or inﬁltrating myeloid cells during early infection (Feuer et al., 2005)
(Fig. 2). The proliferative status of these cells may provide an
additional level of susceptibility to infection (Feuer et al., 2002,
2003, 2005; Feuer and Whitton, 2008).Coxsackievirus infection of neural progenitor and stem cells
What might be the beneﬁt of CVB3 targeting NPSCs for infection?
We expect that the beneﬁts may be many fold in terms of viral
replication, persistence, dissemination, and transmission. First, NPSCs
actively proliferate not only during neonatal development, but also
occasionally within the adult host. Infection of NPSCs may assist in
expanding the tropism of CVB3 upon their differentiation into the
three neural lineages — neurons, astrocytes, and oligodendrocytes.
Previously, we determined that CVB3 preferentially replicates within
actively proliferating cells (Feuer et al., 2002). Hence, NPSCs may be
considered ideal host cells for infection.
Second, NPSCs migrate upon their differentiation into particular
regions within the CNS, including the hippocampus and the olfactory
bulb. The olfactory bulb might be considered an escape route for the
virusupon anterograde transport across the olfactoryneuroepithelium.
Third, NPSCs might be altered upon their differentiation into neurons.
Alterations in neuronal function may lead to behavioral modiﬁcations
within the host, whichmay act tomaximize virus transmission. Fourth,
targeting of NPSCs might be a strategy of CVB3 to establish persistent
infection with sporadic reactivation whenever quiescent stem cells
becomeactivated to generate downstreamprogenitor cells (Fig. 3). The
majority of primary neural stem cells at any moment in time might be
expected to remain within a quiescent state. Therefore, CVB3
replication may be temporarily arrested in the host cell until a later
point in time when the production of virions may be of beneﬁt to viral
transmission, perhaps through the olfactory neuroepithelium. Finally,
normal immune responses may be suppressed within neurogenic
regions, either due to the immunoprivileged status of the CNS, or
potentially reduced antiviral responses in these crucial neural stem
cells.
Enterovirus dissemination — hitch-hiking on migratory
immune cells
Perhaps surprisingly, polarized epithelial cells are not considered
primary target cells for CVB3 infection in vivo, despite their expression
Fig. 2. Induction of CCL12 and the progressive extravasation of infectedmyeloid cells through the basement membrane as determined by confocal microscopy and Imaris 3D analysis.
One day-old C57 BL/6 mice were intra-cranially infected with a recombinant coxsackievirus B3 expressing eGFP (eGFP-CVB3; 10E7 pfu). The brains were harvested 12 h later and
inspected by confocal ﬂuorescence microscopy. Myeloid cells responding to CVB3 infection were observed entering through the tight junctions of the choroid plexus epithelium. As
these myeloid cells entered the lateral ventricle, they expressed high levels of viral protein (green). Also, the chemokine CCL12 (red), a potential chemoattractant molecule for
inﬁltrating myeloid cells, was expressed within the choroid plexus and surrounding subventricular zone. The kinetics of myeloid cell migration through the basement membrane
(outlined by laminin staining in red) was observed by confocal microscopy and IMARIS 3D analysis. Immunoﬂuorescence images showed infected myeloid cell migration (green)
through the tight junctions of the choroid plexus epithelium. Gray scale images of all three colors (virus-green; laminin-red, DAPI-blue) at 12 h PI revealed the intensity and
organization of the myeloid cell inﬁltration in greater detail. In order to better visualize myeloid cell entry, IMARIS 3D with diminishing laminin label (diminishing red) was carried
out, and the methodology revealed the extravasation of infected myeloid cells through the basement membrane (white arrow). Original images were obtained with a 63× Plan-
Aprochromat objective at 0.3 μm interval step slices.
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been found to include the acinar cells of the pancreas, cardiomyocytes,
activated lymphocytes within the marginal regions of the spleen,
inﬁltrating nestin+myeloid cells, proliferating NPSCs, and immature
neurons of the CNS. Instead, targeting of intrajunctional proteins such
as CAR by CVB3 might be a sophisticated viral strategy to speciﬁcally
infect migratory immune cells as they undergo diapedesis through the
tight junctions. In this regard, we have recently shown the ability of
CVB3 to infect nestin+myeloid cells upon their inﬁltration across the
tight junctions of the choroid plexus epithelial cells comprising the
blood-cerebral spinal ﬂuid-barrier in response to early CNS infection
(Tabor-Godwin et al., 2010). These infected myeloid cells eventually
migrate into the parenchyma of the brain, thereby assisting in virus
dissemination.
The beneﬁts to virus dissemination by targeting intrajunctional
proteins may be many fold; ﬁrst, virions temporarily attached to
sequestered intrajunctional proteins might ﬁnd themselves in a
perfect location to “hitch-hike” onto a migratory immune cell as these
cells enter sites of inﬂammation or injury in response to early
infection. Second, immune cells responding to inﬂammation or injury
tend to be highly activated or undergoing proliferation, and each virus
may induce unique chemokine proﬁles early after infection to attract
their immune cells of choice. CVB3 has been shown previously to
preferentially replicate within activated or proliferating cells. Third,
virions carried internally by immune cells might temporarily shield
the virus from neutralizing antibodies upon dissemination. Neutral-
izing antibodies are thought to play a major role in limiting EVinfections, and hypogamma-globulinemic patients deﬁcient in hu-
moral immunity are highly susceptible to EV infection. Perhaps not
surprisingly, other viruses have been shown to bind to intrajunctional
proteins (Bergelson, 2009), suggesting that the proposed mechanism
above might be a general feature of virus dissemination within the
host. Therefore, rather than being a hindrance to virus entry — which
might be expected for receptors sequestered within highly inacces-
sible areas— virus evolutionmay have optimized virion attachment to
intrajunctional proteins to maximize viral spread using immune
target cell “Trojan horses” which become infected during their
migration across tight junctions. Supporting this hypothesis, evidence
for viral targeting of lymphocytes or monocytes for spread into
primary target organs and maximal viral replication has been
described for CVB3 (Mena et al., 1999) and other viruses (Noda
et al., 2006).
Routes of enterovirus entry into the CNS
Since EVs, such as PV, are transmitted via the fecal–oral route of
infection, a detailed understanding of how the virus travels from the
gut to the brain is essential in designing strategies to limit EV disease.
Despite the extensive research that has been performed to understand
CNS invasion, many questions remain. Multiple pathways may
actually work in combination to complete this phenomenon. The
twomainmodels of PV entry into the CNS both involve viremia, or the
presence of virus in the blood, after the virus has replicated in the
lymphatic tissues of the gastrointestinal tract. One hypothesis simply
Fig. 3. Potential reactivation of a persistent coxsackievirus infection within quiescent
neural stem cell. Coxsackieviral RNA (squiggly green lines) may persist in a latent state
within quiescent type B neural stem cells in the CNS. Following cellular division
reactivation of viral RNA may lead to viral protein expression and sporadic infectious
virus production. The production of infectious virions may infect nearby progenitor
cells. Alternatively, asymmetric division of infected type B stem cells may generate
downstream progenitor cells or immature neurons that remained infected and migrate
to other regions of the CNS. The outcome over the long-term of continuous virus
reactivation may be virus-mediated neuropathology and virus dissemination.
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barrier (BBB) in an hPVR-independent manner (Yang et al., 1997).
Perhaps direct entry across the BBB via early PV infection of hBMECs
may occur ﬁrst, thus weakening or exposing the BBB and allowing for
secondary virus entry into the CNS regardless of receptor expression.
A secondmodel of EV entry proposes PV spread frommuscle to the
CNS along neural pathways (Ren and Racaniello, 1992). These neural
pathways were more clearly deﬁned by Gromeier and Wimmer in
1998 as retrograde axonal transport of the virus from damagedmuscle to the CNS (Gromeier and Wimmer, 1998). Since muscle
injury has been shown to induce neurological PV infection, the model
is typically referred to as “provocation poliomyelitis”. Initially, it was
proposed that hPVR was necessary for retrograde axonal transport of
the virus along microtubules (Ohka et al., 2004). However more
recently, retrograde transport has been shown to occur independently
of the hPVR (Ohka et al., 2009).
Another emerging model of CNS entry involves the use of EV-
infected immune cells invading the CNS in a “Trojan horse” fashion, as
described above. Of note, PV has been shown to infect monocytes,
macrophages and dendritic cells in an hPVR-dependent manner
(Freistadt et al., 1993; Wahid et al., 2005). In addition, lymphocytes
may play a role in monocyte infection by inducing their activation and
facilitating viral replication (Eberle et al., 1995). Further investigation
has revealed a possible link between PV pathogenesis in the CNS and
monocyte infection, as neurovirulent strains were found to replicate
more efﬁciently in monocytes (Freistadt and Eberle, 1996). As
described above, CVB3 and also EV-71 have been shown to replicate
in immune cells, B-lymphocytes, T-lymphocytes and cells of the
myeloid lineage (Haddad et al., 2004; Vuorinen et al., 1996). Our
laboratory has recently revealed the rapid inﬁltration of a novel
population of nestin+myeloid cells into the neonatal CNS following
CVB3 infection (Tabor-Godwin et al., 2010). These cells are highly
susceptible to CVB3 infection and move into the brain parenchyma
over time, suggesting a role in viral dissemination. The growing
number of studies demonstrating EV infection of immune cells
suggests that further investigation of the “Trojan horse” model of
CNS invasion may be warranted.
Enterovirus quasispecies
Another essential factor in CNS invasion may be the involvement
of EV quasispecies, or genotypic variants of virus populations, due to
mutational errors accumulated during viral replication. These errors
result from the low ﬁdelity of the RNA-dependent RNA polymerase
whereby at least one incorrect nucleotide is incorporated per genome
duplication (Ward and Flanegan, 1992; Ward et al., 1988). Other
contributing factors during viral replication may also increase viral
diversity. For example, a recent in vitro study performedwith PV 3DPol
found that the replication ﬁdelity may be relatively high; yet other
events during replication, such as template switching, may actually
contribute to the errors found in the genome (Freistadt et al., 2007).
Regardless of the nature of mutation rate, the existence of a swarm
of viral variants, or a quasispecies cloud, has been shown to contribute
to EV spread to the CNS. Recent elegant work utilizing a PV variant
encoding a mutation in 3DPol isolated during serial passage in the
presence of ribavirin has revealed the critical nature of viral
quasispecies in contributing to invasion of the CNS. The PV isolate
(G64S) was shown to increase the ﬁdelity of the viral polymerase and
decrease quasispecies diversity (Vignuzzi et al., 2006). The G64S PV
isolate was less neurovirulent than wild type virus, and CNS invasion
failed to occur unless the isolate was co-inoculated in combination
with a diverse quasispecies population. These intriguing results
demonstrated that cooperation between variants within a viral
population was necessary for CNS invasion and the ensuing
neuropathology. Cooperation among viral genotypes might include
evasion of the immune response simultaneously with CNS invasion.
Genetic bottleneck effects have also been observed as viral variants
enter the CNS. As theﬁrst fewviruses enter cellular routes into the CNS,
antiviral responses become initiated which block entry for the
remaining variants (Pfeiffer and Kirkegaard, 2006). This antiviral
genetic bottleneck effect, also referred to as the “burned-bridge”
model, may contribute to the rare transmission of PV into the CNS
which occurs in approximately 1 to 2% of cases (Gromeier and
Wimmer, 1998). Later studies have added to the “burned-bridge”
modelwherebymultiple barriersmay contribute to genetic bottleneck
294 R.E. Rhoades et al. / Virology 411 (2011) 288–305effects of quasispecies. These barriers whichmay limit neurovirulence
include the integrity of the gut, the induction of a protective innate
immune response, and inefﬁciency in neuronal transport of virus (Kuss
et al., 2008; Lancaster and Pfeiffer, 2010). Thus, EV entrance into the
brain appears to be a complicated interplay not only between the virus
and the host, but also among viral variants within the quasispecies
population.Enterovirus tropism
EVs are routinely neurotropic, yet each member of the virus genus
targets different regions of the CNS (Table 1). A recent in vivo study by
Nagata et al. examined the localization of PV and EV-71 following
intravenous infection of monkeys. The authors identiﬁed PV-induced
lesions primarily within the pyramidal tract of the CNS causing a total
loss of motor neurons in the anterior horn of the spine. In contrast, EV-
71 induced only limited damage in both the extrapyramidal and
pyramidal tracts, leaving many motor neurons in the anterior horn of
the spine intact (Nagata et al., 2004). Furthermore, the authors were
able to isolate PV from the entire CNS, including the dorsal root
ganglia and the trigeminal. In contrast, EV-71 could not be isolated
from either of the latter two regions of the CNS. These results illustrate
the broad range of neuronal target cells for PV, as compared to the
more restricted neuronal targets for EV-71.
In yet another example of neuronal targeting of a picornavirus,
TMEVwas shown to initially infect gray matter regions of the CNS, yet
virus persisted in the white matter following acute infection
(Roussarie et al., 2007). Echovirus type 1 (ECHO-1-V) has been
shown to cause cellular necrotic lesions in the cerebral cortices of
transgenic mice expressing human integrin very late antigen 2,
leading to paralysis and wasting (Hughes et al., 2003). In contrast,
early CVB3 infection was found to be localized to speciﬁc neurogenic
regions of the brain, including the subventricular zone (SVZ) (Feuer
et al., 2005).
Each EV genus member clearly prefers distinct regions of the CNS.
Yet, what factors determine preferential tropism at the cellular level?
Tropism at the cellular level can be viewed as an interplay of at least
three general factors: the ability of the virus to infect and replicate in
the speciﬁc host tissues; the capability of the host cell to clear the
virus; and the capacity of the virus to avoid clearance by the host.
Potential differences in the magnitude of the interferon α/β response
may greatly inﬂuence PV tissue tropism (Ida-Hosonuma et al., 2005;
Yoshikawa et al., 2006). The tropism of PV for neurons has previously
been shown to be also determined by the PV Internal Ribosomal Entry
Site (IRES) (Kauder and Racaniello, 2004). Kauder et al. initially found
that the tropism of PV towards nervous tissues could not be fully
explained by organ-speciﬁc differences in IRES-mediated translation
within age-matched samples. They investigated alterations in PV
tropism by generating recombinant viruses engineered to contain the
IRES from human rhinovirus (Kauder et al., 2006). In this manner, the
investigators observed IRES-mediated, organ-speciﬁc translational
differences between EVs in adult versus neonatal infection. They
concluded that these differences might be attributed to IRES trans-
acting Factors (ITAFs) differentially expressed in various cell types,
including neurons.Table 1
Enterovirus tropism in the CNS.
Virus CNS localization Cell types i
Poliovirus Entire CNS Neurons, as
Enterovirus-71 CNS — but not dorsal root ganglia or trigemina Neurons an
Coxsackievirus Choroid plexus, neurogenic regions (SVZ and SGZ),
hippocampus, cortex
Nestin+m
TMEV Gray matter (acute) white matter (persistence) Neurons, asIRES trans-acting factors (ITAFs)
ITAFs have been found to play a key role in EV IRES-mediated
translation initiation. Some IRESs require speciﬁc ITAFs, while others
require few additional proteins (Fitzgerald and Semler, 2009). Hence,
tissue speciﬁc ITAFs may help to explain the tropism of EVs towards
particular tissue types. Neurons may be more susceptible to infection
due to the availability of speciﬁc ITAFs needed to initiate IRES-
mediated translation. Investigation of TMEV and FMDV IRESs
suggested that cell-speciﬁc differences in ITAFs may explain why
some viruses are able to replicate in neurons, while others cannot
(Pilipenko et al., 2000). Furthermore, translation initiation of different
EVs IRES may depend on a combination of different ITAFs and
eukaryotic initiation factors which may have different cell-speciﬁc
levels of abundance (Boussadia et al., 2003). Recently, the Far
Upstream Element (FUSE) binding protein (FBP2), originally identi-
ﬁed to associate with a protein complex involved in intronic c-src
neuronal speciﬁc silencing enhancer, was discovered as a critical ITAF
for EV-71 infection (Lin et al., 2009a).
While the IRES and ITAFs have largely been associated with viral
replication inneurons, EVs are capable of infectingother cell types in the
CNS. For example, PV can infect astrocytes and oligodendrocytes
(Couderc et al., 2002). Also, it has been known for some time that TMEV
can infect astrocytes, yet persist in oligodendrocytes (Rodriguez et al.,
1983). EV-71 has been found to readily infect and replicate in
astrocytoma cultures (Kung et al., 2007) and cultures of rat brain
astrocytes (Tung et al., 2010). We have shown that CVB3 preferentially
infects NPSCs (Feuer and Whitton, 2008), and more recently, a novel
population of nestin+myeloid cells inﬁltrating into the CNS (Tabor-
Godwin et al., 2010). Parechoviruses (P-ECHO-Vs) are suspected to be
taken up by microglia which leads to the activation of these resident
immune cells (Volpe, 2008). Also, microglia, and glial cells may be
potential sites of EV persistence. For example, macrophages and
microglia have been found to be the main reservoir for harboring
TMEV during persistent infection (Roussarie et al., 2007). Respiratory
EV, including rhinoviruses (RVs), have not been historically found to
infect theCNS.However, a recent study suggested that recombinationof
respiratory EV to genetically similar viruses, such as CV and PV, may
eventually lead to respiratory EVs with tropism for the central nervous
system (Tapparel et al., 2009). This possibility is not implausible,
especially with the recent ﬁndings suggesting the contribution of viral
variants or quasispecies to PV spread into the CNS (Vignuzzi et al.,
2006).
Immune responses to enteroviruses
The immune response plays a critical role in protecting the host
from viral pathogens by both modulating the release of chemokines
and inﬂammatory cytokines for leukocyte recruitment, and by
directly ﬁghting infection via the interferon response. An informative
review of chemokine induction in response to neurotropic infections
has recently been published by Hosking and Lane (2010). These
chemoattractant molecules may be especially critical to combating
microbes within immunoprivileged sites, such as the CNS. We have
demonstrated the induction of numerous chemokines in the CNS
following CVB3 infection. One particular chemokine, CCL12, may playnfected — acute Cell types infected — persistence
trocytes, and oligodendrocytes Neurons
d astrocytes Persistence documented; site unknown
yeloid cells, NPSCs, and neurons NPSCs (in culture)
trocytes, and oligodendrocytes Macrophages, microglia, and oligodendrocytes
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inﬁltrate across the blood-CSF-barrier and become infected upon their
entry through the choroid plexus (Tabor-Godwin et al., 2010).
“Bystander” casualties suffered upon activation of cytolytic T cells
during an adaptive immune response within the CNS may be
potentially more devastating to neurons than a viral infection itself.
Thus, the host may restrict or control immune responses in response
to a viral infectionwithin immunoprivileged sites; this restrictionmay
partly explain why certain viruses may preferentially target the CNS.
Innate immune response following enterovirus infection
The innate immune response begins with the recognition of the
virus by cytoplasmic sensors. EVs have been shown to activate
essential innate immune response molecules, including Toll-like
Receptor 3 (TLR3), Retinoic Acid Inducible Gene I (RIG-I), and
Melanoma Differentiation-Associated Gene 5 (MDA5). TLR3 is located
on the membrane of endosomes or the plasma membrane and
recognizes double-stranded RNA, a structure generally observed
during viral replication of all RNA viruses. Recent studies suggest
that TLR3 plays a strong role in cardioprotection against EV infections
and may depend on autophagic processes (Gorbea et al., 2010).
Studies of the recognition of EVs by cytoplasmic sensors of the innate
immune response have largely centered on DExD/H-box-containing
RNA helicases, such as RIG-I and MDA5. In examining encephalo-
myocarditis virus (EMCV) induction of the type I interferon (IFN)
response in mouse embryonic ﬁbroblasts, Kato et al. concluded that
MDA5, but not RIG-I, was critical for picornavirus detection (Kato
et al., 2006). However, this does not mean that RIG-I is excluded from
picornavirus detection. By utilizing MDA-5 knockout mice, Papon et
al. observed that RIG-I was also useful in detecting EMCV (Papon et al.,
2009). Both of these sensors may play important roles in EV detection
by the host. EVs may circumvent the action of these molecules by
encoding proteins that affect their signaling pathways.
Once a pathogen is recognized, the innate immune response may
play a substantial role in initiating virus-mediated neuropathology
following EV infections. For example, the severity of echovirus and EV
infections in the CNS have been associatedwith higher systemic levels
of proinﬂammatory cytokines like IL-6, IL-1β, and TNF, which can lead
to greater cytokine-induced tissue destruction (Lin et al., 2003; Liu
et al., 2005). Also, CV activation of the inﬂammatory response has
been shown to cause extensive inﬁltration of leukocytes into the CNS
thereby causing inﬂammatory lesions and contributing to neuropa-
thology associated with the virus (Feuer et al., 2009).
In addition to the potentially harmful inﬂammatory responses
triggered within the CNS, EV infections may also initiate the type I IFN
response pathway. TLR-3, RIG-1, and MDA5 are all able to induce the
type I IFN response. TLR-3 induces the production of type I IFNs by
activating the transcription factors Interferon Regulatory Factor 3
(IRF3), NF-κB, and AP-I through the adaptor protein TIR-domain-
containing Adapter Inducing Interferon β (TRIF) (Matsumoto and
Seya, 2008; Wilkins and Gale, 2010). The RIG-I and MDA-5 pathways
are distinct and independent of the TLR-3 pathway. RIG-I and MDA-5
both interact with the adaptor molecule IPS-1 through their CARD
domains. IPS-1 transfers the activation signal to downstream kinases,
which in turn activate IRF-3 and other transcription factors involved
in type I IFN induction (Kato et al., 2006). Malathi et al. determined
that the helicase activity of RIG-I and MDA5 may have important
autoregulatory roles and work in concert with Endoribonuclease L
(RNase L) to produce small self RNA cleavage products that can
interact with RIG-I or MDA5, thereby amplifying the signal (Malathi
et al., 2007).
Following their induction, type I IFNs bind to their receptors either
on the same cell or on neighboring cells. Binding of type I IFNs to their
receptor induces the transcription of antiviral miRNAs and IFN
Stimulated Genes (ISGs) through the JAK/STAT pathway. Many ofthese ISGs encode antiviral products or serve to further upregulate the
type I IFN pathway. For example, RNase L is an ISG that contributes to
the ampliﬁcation of the type I IFN response, but also cleaves viral RNA
and inhibits their translation. Furthermore, the antiviral activity of
RNase L has been found to have a protective role in the CNS against
coronavirus-induced demyelination. In comparing wildtype and
RNase L−/− mice, Ireland et al. found that RNase L deﬁciencies
increased demyelination and axonal damage in the brain following
infection, and affected the regulation apoptosis (Ireland et al., 2009).
Additional ISGs encode products that can inhibit speciﬁc viruses.
Additionally, IFN-β has been found to modulate the expression of
antiviral microRNAs in response to RNA viruses, including hepatitis C
(Pedersen et al., 2007). Hence, it is reasonable to suspect that type I
IFN-induced antiviral miRNAs might play an important role in host
defense against EVs in the CNS.
EVs have evolved a surprising number of mechanisms for under-
mining the host innate immune response, attacking at different stages
of the IFN induction and response pathways. EV and cardiovirus (such
as TMEV) proteins may counter-act host defenses (Agol and Gmyl,
2010). The ability to evade the host antiviral response may be an
important contributing factor not only for maximizing acute infection,
but also for the successful establishment of viral persistence. PV,
rhinovirus (RV), and EV have been found to reduce RIG-I levels and
disrupt RIG-I mediated interferon signaling (Barral et al., 2009). A
reduction in RIG-I levels has been attributed to the activity of the PV
3C protease. PV and RV type-1a have also been observed to cleave
MDA5 through a caspase and proteasome-dependent mechanism
(Barral et al., 2007). Since RIG-I signaling induces further RIG-I
expression, and MDA5 provides secondary protection against viral
infection in the host cell, EVs may also target the downstream
signaling pathways for these molecules. The 3C protease of EV-71 has
also been found to disrupt RIG-I signaling through a protease-
independent fashion. Instead of cleaving, 3C protease binds to RIG-I
and prevents the recruitment of IPS-1 (Lei et al., 2010). In contrast,
RV-14 attenuates the type I interferon response by targeting the
activation of IRF-3 upon identiﬁcation by MDA5 (Kotla et al., 2008).
Similarly, TMEV has been found to inhibit IRF-3 dimerization (Ricour
et al., 2009).
Once the antiviral response has been initiated, viruses have
developed ways to combat these protective actions. PV and RV have
been found to cleave Nup62 (Park et al., 2010) and degrade Nup153
and Nup98 (Park et al., 2008). By altering the nucleus by degrading
nuclear pore complex proteins, viruses can affect host mRNA and
protein localization, and shut down host protective factors. The
hyperphosphorylation of Nup98 by the L protein during TMEV
infection has been shown to block host mRNA export from the
nucleus (Ricour et al., 2009). Herpesvirus genomes have been found
to encode miRNAs suggesting that they exploit the host miRNA
machinery to regulate the expression of host and viral genes (Pfeffer
et al., 2005). Although this mechanism has not been demonstrated for
EVs, Pelletier et al. have found that cells exposed to and cured of PV
using RNAi respond more quickly to RNAi treatment, as compared to
cells never having been exposed to PV (Pelletier et al., 2010). These
intriguing results suggest that cellular miRNA processing machinery
plays an antiviral role during EV infections, as well. Furthermore, cells
which have successfully cleared the virus may be permanently altered
to better respond to future viral infections.
Adaptive immune response following enterovirus infection
Numerous clinical case reports involving patients suffering from
encephalitis due to EV document the importance of neutralizing
antibodies in controlling infection (Xie et al., 2010). The signiﬁcant
contribution of a neutralizing antibody response in controlling
infection is also shown by studies describing individuals suffering
from agammaglobulimia. The absence of neutralizing antibodies in
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EV infections of the CNS that can lead to chronic neuropathies
(Misbah et al., 1992). Experiments evaluating CVB3 infection in mice
lacking B cells (BcKO mice) indicate that antibodies are critical for
viral clearance (Mena et al., 1999). The role of B cells in controlling
CVB3 infection may be more complex by evidence suggesting B cells
may contribute to virus dissemination via the “Trojan horse”
hypothesis. Early after infection in normal mice, high levels of viral
RNA was observed in proliferating lymphocytes located within the
marginal zone of the spleen.
Macrophages and microglia may be involved in EV clearance
within the CNS. These phagocytic cells are thought to be early
responders to viral infection. The presence of activated microglia and
macrophages in response to CVB3 infection has been observed in our
neonatal mouse model (Feuer et al., 2009). By confocal microscopy,
Iba1+ macrophages/microglia within the CNS were shown actively
engulﬁng virally-infected cells.
T cells also play a critical role in the adaptive immune response to
EV infection in the CNS; however, bystander damage following their
activation may be signiﬁcant. Much work in understanding T cell
responses to picornavirus infection in the CNS and the ensuing
immune-mediated pathology has been described for TMEV during
acute and persistent infection. A highly detailed and informative
review on TMEV-induced molecular mimicry model of multiple
sclerosis has been published (Olson et al., 2005). Inﬁltration of CD4+
and CD8+ lymphocytes within the CNS has also been shown following
EV infection (Lin et al., 2009b). Exacerbation of virally-induced
morbidity may occur in mice deﬁcient in CD4+ and CD8+ lympho-
cytes, indicating that T cells are necessary to combat infection. In
contrast, some EVs such as CVB3, have evolved ways to escape
detection by CD8+ T cells via the inhibition of antigen presentation by
theMHC class I pathway (Kemball et al., 2009). Therefore, activation of
the T cell response may vary greatly, depending upon the EV genus
(Slifka et al., 2001).Enterovirus persistence
Although EV possess multiple mechanisms by which they can
evade the host immune response, their success is not absolute, and
the struggle between the host and virus can last for very long periods
of time. EV persistence appears to be the product of the ongoing
attempt of the host to eliminate or suppress virus replication, and the
virus' struggle to remain intact in a hostile cellular environment.
Under the selective pressures generated by a successful host immune
response, sometimes the best defense for the virus is simply to
mutate. As described above, errors in EV replication can lead to the
existence of viral quasispecies (Domingo et al., 2008) which may
broaden the tropism of EV (Vignuzzi et al., 2006), assist in evasion
from the immune response, and lead to persistence. Thus, perhaps it
comes as no surprise that EVs may persist in the CNS and avoid
clearance by the host.
EV-71, PV, CVB3, and TMEV all havemechanisms formitigating the
host innate immune response. These viruses have been observed to
persist long after the initial infection. Evidence of EV-71 persistence in
a clinical setting has been observed by the continued detection of
virus sequences in the excretions and secretions of patients long after
the detection of the initial infection (Han et al., 2010). Whether or not
the CNS is a potential site of the EV-71 persistence has not yet to be
determined. In the case of TMEV, virus has been found to persist in
oligodendrocyte cell cultures, but the main reservoir for persistent
TMEV may be macrophages (Roussarie et al., 2007). Upon infection,
TMEV is transferred from the neuronal axon to the oligodendrocyte in
a myelin-mediated fashion; following the ingestion of infected
oligodendrocytes, macrophages become the primary reservoir for
TMEV persistence.PV has previously been demonstrated to persist in primary neural
cell cultures (Colbere-Garapin et al., 1998). PV persistence and
reactivation has been a suspected cause of Post-Polio Syndrome
(PPS) (Baj et al., 2007). Indeed PV RNA could be detected in some
patients with PPS, though the persistent virus may be very different
from the wild type strain (Baj et al., 2007). The low viral load and the
unclear mechanism of reactivation for mutated virus in PPS patients
most likely fuel the controversy regarding the potential contribution
of persistent PV material to recurring disease. Perhaps PV persists in
an attenuated form in peripheral nervous tissues of the host at low
replication rates; a reactivation event, such as injury, might trigger
higher levels of viral replication with ensuing neurological sequelae.
Injury-mediated retrograde axonal transport of PV has been demon-
strated to carry PV into the CNS (Gromeier and Wimmer, 1998), and
may be a mechanism by which PV can be transported from sites of
persistence back to the CNS.
CV persistence in the heart has been the subject of much
investigation, and its persistence in the CNS has only recently been
described (Feuer et al., 2009). In the heart, CV persistence is associated
with chronic myocarditis and dilated cardiomyopathy (Chapman and
Kim, 2008). The host innate immune response, in particular the type I
IFN response, is extremely critical for controlling CV infection of the
heart (Deonarain et al., 2004). The type I IFN response might also
create selective pressures resulting in viral genomemutations (Kim et
al., 2005b), attenuation of CV, and persistence in the heart. Genome
deletions in the 5′ UTR of CVB3 were recently observed upon passage
of CVB3 in primary heart cell cultures. These deletionswere associated
with a reduction in cytopathic effects (cpe) without reductions in viral
titers (Kim et al., 2008). Similarly, persistent CVB3 RNA was detected
in the CNS of mice following neonatal infection for up to 90 days post-
infection (PI), as determined by nested RT-PCR, in the absence of
infectious virus by plaque assay (Feuer et al., 2009). Our most recent
results suggest that CVB3-infected neurospheres, or NPSCs grown in
culture as free-ﬂoating structures, may support a persistent or carrier-
state infection (manuscript submitted). Based on these results, we
hypothesize that neurogenic regions of the CNS may be potential sites
of CVB3 persistence in vivo. Perhaps CVB3 reactivation is induced
upon occasional proliferation and asymmetric division of resting or
quiescent type B neural stem cells harboring persistent virus within
the CNS (Fig. 3), thereby leading to intermittent replication of virus.
The possible persistence and reactivation of EV in a clinical setting
is of profound importance, especially with the addition of immuno-
suppressive drugs, such as Rituximab, given to patients suffering from
B cell lymphomas. Immunosuppression, especially with drugs target-
ing the humoral immune response, may lead to reactivation/increased
replication of persistent EV in the CNS with potentially dangerous
neurological complications (Schilthuizen et al., 2010; Servais et al.,
2010).Pathophysiology of enterovirus infection
EV infection of the CNS has been associated with acute ﬂaccid
paralysis (Solomon and Willison, 2003), acute disseminating myelitis
and acute transverse myelitis (Agin et al., 2010; Minami et al., 2004).
Aseptic meningitis and encephalitis can also result from EV infection
(Dalwai et al., 2010; Lewthwaite et al., 2010). Further evidence
indicating the extensive distribution and diversity of EVs associated
with human disease is demonstrated by a recent informative
publication by Victoria et al. (2009). Their metagenomic analyses
suggested the presence of circulating human EV species A (HEV-A)
through HEV-C, including other members of the Picornaviridae, such
as P-ECHO-Vs, rhinoviruses, and human cardioviruses in South Asian
children suffering from acute ﬂaccid paralysis. Metagenomic analysis
may be a highly informative technique in determining the distribution
and number of circulating EVs in human populations.
Fig. 4. Increased susceptibility of young mice to coxsackievirus infection and
subsequent CNS pathology. Neonatal SJL mice (days 1, 2, or 6 post-birth) were intra-
cranially infected with 100 pfu CVB3. The brains of infected mice were harvested on
days 11, 15 or 33 post-infection, respectively. De-parafﬁnized sections of the brains
were stained with hematoxylin and eosin and inspected by microscopy for lesions and
inﬂammatory cells. (A) One day-old mice suffered the greatest level of neuropathology
following infection. Lesions were observed within the cortex and hippocampus (black
arrows). (B) A higher magniﬁcation of (A) revealed the loss of pyramidal neurons in the
hippocampus and the presence of inﬂammatory cells (black arrows). (C) In contrast,
two day-old mice infected with an identical amount of CVB3 showed reduced signs of
neuronal loss restricted to the CA3 and CA4 ﬁeld of the hippocampus (black arrow). The
presence of immune cell enriched perivascular cuffs were observed near the
hippocampus (black arrow). (D) Six day-old mice infected with CVB3 showed little
or no signs of CNS disease.
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A variety of differing techniques have been used in the clinical
diagnosis of EV infections of the CNS (Table 2); a comprehensive
description of which is beyond the scope of this review. The
GreeneChip pioneered by Ian Lipkin represents the technological
forefront of pathogen identiﬁcation, but has yet to be employed in the
context of EV infections of the CNS (Hunter, 2008). Diagnosis via
selective culture using transgenic cell lines is limited and hindered
primarily by the absence of cell lines supporting strain-speciﬁc
replication (Leland and Ginocchio, 2007). In contrast, molecular
techniques, such as RT-PCR, represent a sensitive and precise
methodology for identiﬁcation of EV CNS infection. Cerebrospinal
ﬂuid (CSF) from afﬂicted patients is the preferred source of clinical
sample upon which these techniques can be performed. Genomic
analysis using RT-PCR can be completed within 24 h of sample
collection (Romero, 1999). RT-PCR diagnosis of enteroviral meningitis
has been performed using primers recognizing a conserved region
within the 5′ UTR (Rotbart, 1990). While genus level identiﬁcation of
EVs is clinically relevant and can be used to guide antiviral regimes,
strain-speciﬁc genotyping is required in some instances. RT-PCR
characterization of the VP1 region has lead to strain-speciﬁc
phylogenetic classiﬁcation (Mirand et al., 2008). Sequencing of the
VP4 and VP2 regions was performed in instances where molecular
typing using the VP1 region was inconclusive. These studies indicate
that RT-PCR is an effective and clinically feasible technique for the
identiﬁcation of the speciﬁc EV strain present in clinically obtained
CSF samples.
Quantitative Real-Time PCR (qRT-PCR) may be a more sophisti-
cated molecular method utilized to detect the amount of EV in clinical
CSF samples (Dierssen et al., 2008). The majority of qRT-PCR assays
identifying EV use the primer pair designed by Robart et al. in 1990,
although variations of these primers do exist (Rotbart, 1990). A
limitation of the technique involves the absence of ampliﬁcation
curves for samples containing mutations in the probe binding region
(Hymas et al., 2008).
Contributions of apoptosis to enterovirus disease in the CNS
We have previously described the induction of CNS lesions (Fig. 4),
inﬂammation, and apoptosis within CVB3-infected neurons in the
cortex and hippocampus (Feuer et al., 2003). TUNEL staining showed
colocalization of infection and apoptosis within the CNS following IC
inoculation of our neonatal mouse model with a recombinant CVB3
expressing eGFP (eGFP-CVB3). A direct overlap of infection and
activated caspase-3 protein revealed infected cells undergoing early
stage apoptosis. Also, infection of virally-infected neuronal precursor
cells contributed to the generation of lesions within the CNS. We also
recently revealed the induction of apoptosis in the choroid plexus
(Tabor-Godwin et al., 2010) following CVB3 infection. These results
suggest that EV may compromise the function of the choroid plexus,
an essential organ involved in CSF production and immune regulation.Table 2
Methods used to identify and classify enterovirus CNS infections.
Technique Method of identiﬁcation Host iso
Tissue culture (Leland, 2008) Presence of cellular
cytopathic effect
Cerebra
Reverse-transcription polymerase chain
reaction+genomic sequence (Romero, 1999)
Genomic ampliﬁcation Cerebra
Quantitative real time PCR (Dierssen, 2008) Genomic ampliﬁcation Cerebra
Immunohistochemistry Visualization using virally
speciﬁc antibodies
Central
system
In situ hybridization Visualization using virally
speciﬁc probes
Central
systemThe observation of hydrocephalus in mice following CVB3 infection
may be related to choroid plexus dysfunction following infection.
Reports also indicate that PV infection may be associated with
induction of apoptosis in the CNS (Girard et al., 1999). DNA
oligonucleosomal laddering and enzyme-linked immunosorbent
(ELISA) assays performed upon CNS samples obtained from mice
exhibiting paralytic poliomyelitis indicated the presence of cells
undergoing apoptosis. These studies indicate that EVs are capable of
inducing apoptosis within the CNS.
Potential behavior and memory dysfunction following
enterovirus infection
The presence of infected neurons and ongoing apoptosis in the
hippocampus and other regions of the CNS is highly suggestive that
memorydysfunction or behavior changesmight be expected following
EV infection. Previous studies have suggested a link between EVlate Tools Speciﬁcity
l spinal ﬂuid Selective cell lines Genus
l spinal ﬂuid Enterovirus speciﬁc primers—majority
amplify 5′ UTR (Rotbart, 1990)
Serotype — nucleotide
mutations (Mirand, 2008)
l spinal ﬂuid Enterovirus speciﬁc primers —
majority amplify 5′ UTR
Genus
nervous
tissue
Visualization/microscopy Cellular localization
nervous
tissue
Visualization/microscopy Cellular localization
298 R.E. Rhoades et al. / Virology 411 (2011) 288–305infection early in childhood and the development of schizophrenia
(Rantakallio et al., 1997; Suvisaari et al., 2003). EV infection of the CNS
occurring during childhood is also associated with long term
neuropathies including delayed neurodevelopment and reduced
cognition (Chang et al., 2007). Clinical examination of placental
samples from newborns exhibiting neurodevelopmental defects has
revealed the presence of EV within the tissue (Euscher et al., 2001).
EV-71 has speciﬁcally been implicated as the causative agent of
developmental defects in the CNS (Huang et al., 2006). Infection of
pregnant mice with polyinosinic–polycytidylic acid, a compound that
mimics replicating virus, may lead to inhibition of embryonic neuronal
stem cell development (De et al., 2010). Therefore, developmental
defects observed following EV infection of the CNSmight be attributed,
at least in part, to the abrogation of normal stem cell replicationwithin
the brain.
Experiments using the Morris water maze as an indicator of
memory formation found that mice infected with TMEV which also
can target the hippocampus exhibited a spatial learning deﬁcit (Buenz
et al., 2006). The deﬁcit was correlated with the extent of damage to
the hippocampus resulting from TMEV infection. We are currently
examining the consequences of CVB3 infection on CNS development
and spatialmemory dysfunction.We expect that lasting consequences
on brain function may result following persistent CVB3 infection.
These studies may be highly signiﬁcant in a clinical setting, especially
given that EV infections comprise the great majority of aseptic
encephalitis infections in humans.
Antiviral drugs to treat enterovirus infections — RNAi
based approaches
The idea that RNAi may act as a potent natural antiviral against
RNA viruses in mammalian cells was ﬁrst shown in 2003 (Gitlin and
Andino, 2003). Since then, RNAi has proven to effectively inhibit EV
reproduction both in vitro and in vivo in a variety of cell and mouse
lines in Table 3. Mechanistically, siRNAs inhibit the production of
infectious virions via Dicer recognition of the viral dsRNA formed
during genomic replication (Aliyari and Ding, 2009). Targeted RNAs
are subsequently degraded, effectively hindering the formation of
nascent virions.
The vast majority of siRNAs developed against EV focus upon the
degradation of mRNAs coding for the viral RNA-dependent RNA
polymerase (RdRp) and proteases. For example, siRNAs directed
against protease 2A were the most effective in the inhibition of CVB3
infection in HeLa cells andmurine cardiomyocytes (Yuan et al., 2005).
Interferon receptor knock-out mice transfected with siRNAs targeting
CVB3 protease 2A exhibited increased survival time and attenuated
viral replication when challenged with CVB3 (Merl et al., 2005). The
19-mer siRNAs targeting the viral 3Cpro region of coxsackievirus B4
(CVB4) were effective in decreasing viral replication in rhabdomyo-
carcoma cells (Tan et al., 2010). siRNAs targeted against the 3DPol of
EV-71 has also proven protective against this virus in vivo (Tan et al.,
2007). Prophylactic treatment of suckling mice with siRNAs prior to
viral inoculation decreased the level of hind limb paralysis and weight
loss associated with EV-71 infection. Also, RT-PCR and western blotsTable 3
Compounds used to treat enterovirus infections.
Compound Target Stage of development BBB penetra
Ribavirin
(Li, 2008)
Viral genome Patient prescription Conﬂicting re
(Hosoya 200
Pleconaril
(Pevear, 1999)
VP1 protein of
nucleocapsid
Clinical-phase III–IV
(Webster, 2005,
Desmond 2006)
Yes
(Schmidtke,
RNAi (multiple
formulations)
Viral genome —majority target
protease 2A+3C or polymerase
3D (Yuan, 2005; Tan, 2010, 2007)
In vitro/in vivo
(Li, 2008)
Undocumendemonstrated a decrease in viral replication and viral protein
expression levels within the intestines of siRNA-treated mice.
EVs are especially prone to the formation of escape mutants due to
the absence of an RdRp proofreading mechanism. The low ﬁdelity of
the RdRp increases the likelihood of mutants escaping the therapeutic
effects of RNAi. The formation of escape mutants resistant to anti-CV
siRNAs has been documented (Merl and Wessely, 2007). PV escape
variants against siRNAs evolve to incorporate a single nucleotide
mutation located in the center of the targeted RNA (Gitlin et al., 2002).
One strategy to combat this phenomenon may be the simultaneous
administration of multiple siRNAs. The administration of a cocktail
consisting of three distinct siRNAs may reduce the number of escape
mutant progeny to extremely low levels (Merl and Wessely, 2007).
Targeting receptors of viral entry with RNAi may be another strategy
of effectively inhibiting EV replication. siRNAs directed againstmurine
CAR (mCAR) decreased CVB3 titers in mice (Werk et al., 2005). RNAi
degradation of host genes constitutes a unique approach which may
mitigate the formation of potential viral escape mutants by affecting
cellular targets, as opposed to viral targets.
The development of therapeutic siRNAs symbolizes a novel and as
of yet, undeveloped candidate for the treatment of EV infections of the
CNS (Vaishnaw et al., 2010). However, RNAi as antiviral therapy has
yet to be employedwithin the CNS. Once the hurdle of delivering RNAi
therapeutic constructs to the CNS has been overcome, siRNAs could
potentially be used to treat life-threatening EV infections. EV
infections of the CNS rarely occur in the absence of infection of
peripheral tissues outside the brain. Therefore, even if a therapeutic
agent has not been demonstrated to hinder virus production within
the CNS per se; by inhibiting replication in other tissues, an siRNA-
based drug might impede virus growth and the eventual progression
of disease into the CNS. In summation, RNAi represents an immature
yet powerful tool that should not be overlooked in the development of
therapeutics designed to treat EV infections of the CNS.
Antiviral drugs to treat enterovirus infections — ribavirin
Ribavirin (1-(_-d-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide)
was ﬁrst synthesized in 1972 by ICN pharmaceuticals. Currently under
clinical development as a broad-spectrum antiviral, ribavirin has been
shown to inhibit the replication of a variety of EVs. Ribavirin, a
nucleoside analog, may act as amutagen via incorporation into the viral
RNA genome (Crotty and Andino, 2002; Crotty et al., 2000, 2001). The
presence of ribavirin may force the afﬂicted virus into “Error
catastrophe” by generating a highly variable noninfectious quasispecies
swarm and thereby causing lethal mutagenesis (Vignuzzi et al., 2006).
Ribavirin has been found to inhibit both in vitro and in vivo EV-71
replication (Li et al., 2008). Human neuronal and mouse neuronal cell
lines treated with ribavirin showed decreased signs of cpe following
EV-71 infection. Also, ribavirin-treated mice exhibited decreased
mortality, morbidity, and paralysis rates when challenged with EV-71
(Li et al., 2008).
There are conﬂicting reports on the ability of ribavirin to cross
the BBB; a necessary criterion when dealing with the treatment of
EV infections of the CNS. Upon treatment of subacute sclerosingtion Resistance Mechanism
ports
1+Honda 1994)
Yes (Poliovirus Isolates)
(Vignuzzi, 2005+Pfeiffer 2003)
Nucleoside analog— genomic
incorporation— error catastrophe
2009)
Yes (CVB3 Nancy Strain)
(Schmidtke, 2005)
Conformational change of VP1
protein — receptor attachment —
genomic uncoating (Chen, 2008)
ted Yes (Coxsackie+
Poliovirus Isolates)
(Merl, 2007; Gitlin, 2002)
Viral RNA degradation via Dicer
recognition (Aliyari, 2009)
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measles infection, only direct intracranial (IC) and not IP administra-
tion of RBV diminished the effects of this virus (Honda et al., 1994).
Combining the drugwith the lipophylic carriermolecule, cyclodextrin,
may increase the concentration within the CNS following IP injection
(Jeulin et al., 2009). Ribavirin has also been combined with IFN-α
therapy to treat SSPE (Hosoya et al., 2001). Patients received
intravenous (IV) ribavirin, as well as intraventricular IFN-α treatment.
Upon treatment with ribavirin (20 mg/kg), high performance liquid
chromatography quantiﬁcation indicated that the compound was
present within the cerebral spinal ﬂuid of one patient at a
concentration of 7.5 μg/ml, a concentration shown to inhibit the
replication of SSPE in both tissue culture and mouse studies (Hosoya
et al., 1989; Ishii et al., 1996). Therefore, ribavirin may be capable of
crossing the blood brain barrier (BBB) in sufﬁcient quantities and to
inhibit viral replication. In our neonatal model of CVB3 infection, IP
administration of ribavirin led to brain wet weight recovery
(manuscript in preparation) indicating that the compound may cross
the BBB in effective quantities to reduce CVB3 replication during
persistent infection.
EV resistance may necessitate the development of new antiviral
drugs to combat these nefarious pathogens. Resistance against
ribavirin by PV has been recently observed (Vignuzzi et al., 2006).
PV may combat the effects of ribavirin via a single point mutation in
the RdRp, effectively increasing the ﬁdelity and lowering the viral
genomic mutation rate (Pfeiffer and Kirkegaard, 2003). Intriguingly,
the emergent ribavirin-resistant quasispecies swarm may be less
adaptable to a changing environment.
Antiviral drugs to treat enterovirus infections — pleconaril
Pleconaril,3-(3,5-dimethyl-4((3-(3-methyl-5-isoxazolyl)propyl]
oly)phenyl)-5-(triﬂuoromethyl)-1,2,4-oxadiazole is currently licensed
by Schering Plough and has been developed as an anti-picornaviral drug
with demonstrated efﬁcacy against many EVs (Pevear et al., 1999).
Pleconaril is able to cross the BBB and remain within the CNS at
concentrations that inhibit EV replication (Schmidtke et al., 2009). The
mechanism of action for pleconaril against viral pathogens is two-fold;
the compound inhibits both viral attachment to the cognate receptor
and uncoating of the nucleocapsid during replication (Chen et al.,
2008b). Pleconaril inhibits viral attachment by binding to the VP1
protein present in the canyon ﬂoor or ‘pocket’ of the nucleocapsid and
inducing a conformational change in the protein. This conformational
change synergistically inhibits the release of the viral RNA from the
nucleocapsid, effectively hindering replication. Tissue culture and
animal challenge studies testing the susceptibility of clinical EV isolates
to the drug have demonstrated antiviral activity (Pevear et al., 1999).
Also, numerous case studies evaluating the efﬁcacy of pleconaril to treat
clinically ill patients including immunocompromised individuals have
beendescribed (Desmondet al., 2006;Webster, 2005). A previous study
has suggested that the Nancy strain of CVB3 may be resistant to
pleconaril (Schmidtke et al., 2005). This resistance was found to be due
to a pointmutation at amino acid 1092 of the CVB3 open reading frame.
Resistance was associated with a leucine at this position, whereas
isoleucine and valine were associated with susceptibility to pleconaril.
In summation, these studies demonstrate that pleconaril may be a
valuable compound in the treatment of some EV infections of the CNS.
Intra-venous immunoglobulins to treat enterovirus infections
The standard therapy for aseptic meningitis caused by EV infection
continues to be intra-venous immunoglobulin (IVIg) treatment,
although the efﬁcacy has not been proven (Abzug, 2004). IVIg is
typically prepared from pools of plasma samples from healthy donors
(Cheng et al., 2008). This passive immunization-based therapy might
neutralize infectious virus circulating within the host, in addition toother non-speciﬁc inﬂammatory mechanisms (Ooi et al., 2010). Fig. 5
illustrates the mechanism of action for each of the antiviral
compounds and IVIg, described above. In addition, novel antiviral
therapies against EVs continue to be developed (Wu et al., 2010).
Vaccines against enteroviruses
The historical Salk and Sabin vaccines against PV demonstrate the
effectiveness of immunization in protecting the host against EV
infections. Many effective vaccines stimulating both the innate and
adaptive immune response have been designed to combat the
remaining clinically relevant EVs. To combat EV infection, the adaptive
immune response employs both T cells and antibodies in the clearance
of the virus. Therefore, the most successful vaccines activate both
humoral and cell-mediated immunity and induce lasting viral immu-
nity. The administration of novel vaccines to patients comes with
potential risks, extensive and costly clinical studies, and a potentially
apprehensive public. Unfortunately, acceptance of EV-based vaccines to
the public may not materialize unless the potential diseases caused by
these pathogens become much more widely appreciated. That said,
ongoing EV vaccine studiesmay help us improve the efﬁcacy and safety
of potential vaccine candidates, especially if EV transmission and/or
disease manifestations increase in the general population in the future.
Also “therapeutic vaccines”, those vaccines given after initial infection,
might bemore readily accepted in patients suffering fromEV-mediated
disease. “Therapeutic vaccines” could be envisioned which may
enhance or redirect an ongoing immune response in order to reduce
viral load during early infection, or after the establishment of viral
persistence.
Poliovirus vaccines
Attenuation of EVs through mutations in the genome has
historically led to efﬁcient vaccine production. Perhaps the most
well-known attenuated form of PV is that used for the Sabin vaccine,
which has decreased neurovirulence in part controlled by two stem
loops in the viral IRES (Gromeier et al., 1999). Another mutation that
can cause CNS attenuation is located between the 5′NTR cloverleaf and
IRES and reduces the binding of polypyrimidine tract-binding protein
(Guest et al., 2004). Other studies havemade recombinant viruses that
use the IRES from human rhinovirus type 2 (HRV2) to attenuate
neurovirulence in the Sabin vaccine strain of PV as well as in herpes
simplex virus type 1 (Campbell et al., 2007; Gromeier et al., 1996).
Somewhat alarmingly, a vaccine-derived PV and coxsackievirus A17
recombinant has been generated in the laboratory, thus illustrating the
possibility of such events occurring naturally (Jegouic et al., 2009).
Mutations causing changes in virulence and/or attenuation can
also exist in other regions of the genome. Recent publications have
revealed Sabin vaccine strains that in rare instances caused paralytic
poliomyelitis, havemutations in the capsid protein VP1 representing a
mutational hot-spot (Blomqvist et al., 2010; Rahimi et al., 2007).
Furthermore, defective interfering particles generated through muta-
tions in the capsid region of PV in vitro have been used to investigate
viral replication (Hagino-Yamagishi and Nomoto, 1989). Newer
studies have used cleavage site mutants to learn more about PV
replication and encapsidation, which appear to be separate steps in
the viral life cycle (Oh et al., 2009).
Both inactivated and attenuated forms of the historical PV vaccines
have been used to induce or confer immunity to the virus. The original
formalin-inactivated form of the vaccine (IPV) was developed by
Jonas Salk and licensed in 1955 (Salk et al., 1954). In 1963, an orally
administered live attenuated PV vaccine (OPV) was formulated
(Sabin, 1957). The usage of these vaccines and optimized versions
has severely reduced the incidence of poliomyelitis, although the
pathogen has yet to be eradicated worldwide. Preference for the
administration of the IPV over the OPV is due to the discovery of
Fig. 5. Antivirals against enteroviruses: mechanisms of action. Pleconaril, ribavirin, intra-venous immunoglobulins (IVIg) and RNAi each inhibit the production of infectious virions at
different steps. Pleconaril induces a conformational change in the viral VP1 capsid protein that inhibits both genome uncoating and the binding of the virus to its cognate receptor,
CAR. Ribavirin, a nucleoside analog, is incorporated into the viral genome. This incorporation results in viral genomic mutations that lead to “error catastrophe”. Virus-speciﬁc IVIg
may bind to virions extracellularly and inhibit the virus from entering the cell. RNAimolecules target the positive sense viral RNA strand leading to Dicer-mediated degradation of the
viral genome. However, escapemutants may form that avoid the effects of RNAi. Positive-sense strand viral RNA is shown in black; negative sense strand viral RNA is shown in green.
Antiviral compounds are shown in red. The replication complex is shown in blue.
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cVDPVs are virulent PVs derived from the OPV that occur in a small
minority of vaccine recipients. The reversion of cVDPVs from
attenuation to virulence is a direct consequence of the genetic
instability of the vaccine. In 2000, cVDPVs were responsible for a polio
outbreak in the Dominican Republic and Haiti (Olen Kew 2002).
Sequencing determined that the cVDPVs were recombinant viruses.
The derivation of neurovirulent polio strains from the OPV has led to
the “OPV paradox,” which is based upon the idea that complete
eradication of poliomyelitis is contingent upon the elimination of the
attenuated form of the vaccine (Dowdle et al., 2003).
Enterovirus-71 vaccines
There have been a variety of effective vaccines designed against
EV-71. A formaldehyde-inactivated whole virus preparation has been
shown to protect mice from encephalomyelitis caused by EV-71
infection (Ong et al., 2010). Histopathological examination using
EV-71 speciﬁc antibodies revealed an absence of the virus within the
brain stem of immunized mice. Plaque assays using brain stem and
spinal cord homogenates conﬁrmed the absence of infectious virus
within these tissues. Using a unique strategy, transgenic mice were
developed to secrete the VP1 capsid protein of EV-71 into milk
secretions. When the milk from transgenic animals was fed to
neonatal mice, these neonates developed serologically speciﬁc
antibodies against EV-71 and did not exhibit weight loss when
challenged with the virus (Chen et al., 2008a). Also, virus-like
particles, which resemble EV-71 in capsid structure and protein
composition, have been found to elicit a protective humoral antibody
response in animals (Chung et al., 2008). In addition, passiveimmunization protected neonatal mice from EV-71 associated
morbidity when confronted with a lethal dose of virus. A DNA vaccine
coding for VP1 has also been developed (Wu et al., 2001). But in
contrast to the aforementioned vaccines, the VP1-based vaccine was
only partially protective, as shown by a 40% survival rate of mice
inoculated with a lethal dose of EV-71 following vaccination.
Coxsackievirus vaccines
As with EV-71, many researchers have developed effective
vaccines against CV, although no clinically available vaccine currently
exists. Progress has been made using a variety of vaccines strategies
utilizing either DNA plasmids expressing viral proteins, inactivated
virus, or live attenuated forms of virus. A safe and effective RNA
vaccine against CVB3 that produces noninfectious virus has been
recently produced (Hunziker et al., 2004). Genomic mutation via PCR
mutagenesis of the 3CDpro cleavage site present between CVB3
proteins 2A and 2B resulted in an RNA viral genome incapable of
producing infectious virions, yet conferring partial protective immu-
nity. RNA-immunized mice exhibited lower viral titers within the
pancreas and prolonged survival when challenged with CVB3. RNA-
based vaccines are advantageous as compared to DNA vaccines due to
their inability to integrate into host DNA.
Attenuating mutations have also been found in CVB viral capsid
proteins, and administering these attenuated viruses was found to be
protective against lethal re-challenge in the pancreas and heart;
although the CNS was not examined (Dan and Chantler, 2005).
Another successful vaccine in mice designed against CVB3 involved
the generation of recombinant plasmids expressing capsid proteins.
Two independent plasmids encoded the VP1 and VP3 capsid epitopes
301R.E. Rhoades et al. / Virology 411 (2011) 288–305induced the production of virally speciﬁc antibodies following in vivo
electroporation (Park et al., 2009). Although vaccinated mice
displayed a reduction in virally induced heart injury, the induced
antibodies failed to neutralize infectious CVB3 in culture. Attenuated
CVB3 strains have also been used as potential vaccines and may
represent the forefront of the ﬁeld (Kim et al., 2005a). Whether any of
the aforementioned vaccine candidates are capable of preventing CV
pathology within the CNS has yet to be conﬁrmed.
Studies using EVs have also been used as a model system for the
development of innovative vaccine strategies. “High ﬁdelity” RNA
viruses isolated upon serial passage in the presence of low concentra-
tions of ribavirin might be a general strategy for viral attenuation by
decreasing the level of viral quasispecies (Vignuzzi et al., 2008).
Another original approach to vaccine design involved encoding a
mutant PV that containedhundreds to thousands of under-represented
codon pairs in the PV non-structural proteins (Coleman et al., 2008).
This codon-altered PV had the same amino-acid sequence as wild-type
PV, yet suffered from a decrease in the virus protein translation rate.
Thus, the codon-altered PV could illicit a protective immune response
despite its attenuation (Wimmer et al., 2009). Both of these approaches
greatly decreased the ability of the attenuated “vaccine strain” to revert
to wild-type PV. Importantly both strategies potentially could be
developed quickly for emerging RNA viruses, or for other viruses
whereby vaccine development has been deemed problematic.
Gene delivery in the CNS utilizing enterovirus-based vectors
Due to their remarkable ability to infect the CNS, attenuated EVs
have been explored for use in gene delivery to cells of the CNS. Novel
PV replicons that express green ﬂuorescent protein (GFP) have been
shown to deliver GFP to motor neurons without causing pathogenesis
(Jackson et al., 2001). Also, recombinant PVs designed by the
Gromeier laboratory may be of clinical use for viral gene delivery
into the CNS, or as oncolytic viruses to target glioblastoma cells and
other tumorigenic cells (Goetz et al., 2010). Attenuated CV may also
represent an attractive option; our laboratory and others have shown
the feasibility of generating relatively stable recombinant CVs
expressing such gene products as GFP, dsRED, and renilla luciferase
(Feuer et al., 2005; Kim et al., 2009). Also with their particular stem
cell tropism inmind, attenuated recombinant CVB3may be of value as
a viral gene vector speciﬁcally for delivery of stem cell modulators,
such as transcription factors inducing differentiation, into neural and
embryonic stem cells. However, the high number of circulating
antibodies in the population against EVs (Sawyer, 2002) may limit
their use as vectors in vivo; In contrast, in vitro use may be of great
beneﬁt.
Conclusions and future perspectives
In summary, this review has attempted to cover many of the recent
advances in EV researchwith regard to CNS infection and pathogenesis.
EVs are among the most common and medically important human
pathogens, are a frequent cause of CNS disease (Muir and van Loon,
1997), and may preferentially cause harm in the very young. Much
remains to be learned regarding factors inﬂuencing EV tropism,
activation of the immune response following infection, inﬁltration of
immune cells into the CNS to combat infection, mechanism of
pathogenesis, and antiviral/vaccine development (Nathanson, 2008).
The large number of EV strains circulating in nature hinders the promise
of successful vaccine design against these viruses. The potential
cessation of the globally administered PV vaccine, either due to the
successful eradication of poliomyelitis, or due to dwindling World
Health Organization resources, may lead to emergence of uncharacter-
ized CVs and other related non-polio EVs previously restrained by cross-
reacting antibodies generated through yearly immunizations. These
uncharacterized, yet circulating EV strains with potential CNS tropismmight constitute a new impediment in our control over a devious viral
pathogen. Finally, the ability of EVs to persist in the CNS and target
neural stem cells might suggest lasting effects on brain function. Future
studies might be directed at inspecting possible behavioral alterations
andmemorydysfunction following recovery fromthese challenging, yet
successful neurotropic viruses.
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